19 June 2013
Keywords: archemix, initiates, ph, ii, anti-vwf, drug, trial
Article | 02 April 2009
Archemix, a US privately-held biotechnology company working to develop aptamer-based therapeutics, has initiated a Phase IIa clinical trial of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 April 2009
1 April 2009
3 April 2009
© 2013 thepharmaletter.com